VivoSeq
Oncology

Ewing's Sarcoma

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Ewing's Sarcoma is an early-stage landscape with 0 programs across 2 companies. The most active players are Pfizer, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed9 · 60%
Terminated4 · 27%
Unknown status1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT05440786·46 enrolled
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Completed·Children's Oncology Group·Phase 2·NCT00061893·38 enrolled
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT01696669·43 enrolled
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Completed·MMassachusetts General Hospital·Phase 2·NCT01583543·12 enrolled
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Completed·MMassachusetts General Hospital·Phase 1·NCT01858168·49 enrolled
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
Completed·Children's Oncology Group·Phase 3·NCT00006734·587 enrolled
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Completed·Pfizer logoPfizer·Phase 1/2·NCT00560235·138 enrolled
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Completed·GGradalis, Inc.·Phase 1·NCT02736565·7 enrolled
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Completed·GGradalis, Inc.·Phase 2·NCT02511132·22 enrolled
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00492141·10 enrolled
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Terminated·GGradalis, Inc.·Phase 3·NCT03495921·32 enrolled
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
Terminated·FFudan University·Phase 2·NCT00568464·10 enrolled
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00038142·46 enrolled
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
Unknown status·KKing Faisal Specialist Hospital & Research Center·N/A·NCT00541411·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)